JP2023512151A - Igsf8を標的化することによる自己免疫疾患および癌を治療するための組成物および方法 - Google Patents

Igsf8を標的化することによる自己免疫疾患および癌を治療するための組成物および方法 Download PDF

Info

Publication number
JP2023512151A
JP2023512151A JP2022539749A JP2022539749A JP2023512151A JP 2023512151 A JP2023512151 A JP 2023512151A JP 2022539749 A JP2022539749 A JP 2022539749A JP 2022539749 A JP2022539749 A JP 2022539749A JP 2023512151 A JP2023512151 A JP 2023512151A
Authority
JP
Japan
Prior art keywords
igsf8
antibody
cancer
cells
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022539749A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023512151A5 (cg-RX-API-DMAC7.html
Inventor
シャオレ・リュー
フー,シャオ
シャオ,テンフェイ
Original Assignee
シャンハイ・エックスビーエイチ・バイオテクノロジー・カンパニー・リミテッド
ジーブイ20・セラピューティクス・エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シャンハイ・エックスビーエイチ・バイオテクノロジー・カンパニー・リミテッド, ジーブイ20・セラピューティクス・エルエルシー filed Critical シャンハイ・エックスビーエイチ・バイオテクノロジー・カンパニー・リミテッド
Publication of JP2023512151A publication Critical patent/JP2023512151A/ja
Publication of JP2023512151A5 publication Critical patent/JP2023512151A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/005—Trypanosoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2022539749A 2019-12-25 2020-12-24 Igsf8を標的化することによる自己免疫疾患および癌を治療するための組成物および方法 Pending JP2023512151A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2019128294 2019-12-25
CNPCT/CN2019/128294 2019-12-25
PCT/CN2020/139033 WO2021129744A1 (en) 2019-12-25 2020-12-24 Compositions and methods for treating autoimmune diseases and cancers by targeting igsf8

Publications (2)

Publication Number Publication Date
JP2023512151A true JP2023512151A (ja) 2023-03-24
JP2023512151A5 JP2023512151A5 (cg-RX-API-DMAC7.html) 2023-12-21

Family

ID=76575703

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022539749A Pending JP2023512151A (ja) 2019-12-25 2020-12-24 Igsf8を標的化することによる自己免疫疾患および癌を治療するための組成物および方法

Country Status (11)

Country Link
US (1) US20230056288A1 (cg-RX-API-DMAC7.html)
EP (1) EP4081253A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023512151A (cg-RX-API-DMAC7.html)
KR (1) KR20220151161A (cg-RX-API-DMAC7.html)
CN (1) CN115551549A (cg-RX-API-DMAC7.html)
AU (1) AU2020413633A1 (cg-RX-API-DMAC7.html)
CA (1) CA3165908A1 (cg-RX-API-DMAC7.html)
IL (1) IL294280A (cg-RX-API-DMAC7.html)
MX (1) MX2022008061A (cg-RX-API-DMAC7.html)
TW (1) TW202135861A (cg-RX-API-DMAC7.html)
WO (1) WO2021129744A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230077722A (ko) * 2020-08-10 2023-06-01 지브이20 테라퓨틱스 엘엘씨 Igsf8을 표적화하여 자가면역 질환 및 암을 치료하기 위한 조성물 및 방법

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008535853A (ja) * 2005-04-07 2008-09-04 ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド 癌関連遺伝子
WO2012021840A2 (en) * 2010-08-13 2012-02-16 Biovest International, Inc. Materials and methods for designing autologous idiotype vaccines and treatment of b-cell malignancies
US20120100162A1 (en) * 2006-09-15 2012-04-26 Accentia Biopharmaceuticals, Inc. Cyclophosphamide in Combination with Immune Therapeutics

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2612918T3 (es) * 2013-07-10 2017-05-19 Miltenyi Biotec Gmbh Método para inducir la proliferación de células asesinas naturales por nanomatrices móviles
WO2019084343A1 (en) * 2017-10-25 2019-05-02 The Administrators Of The Tulane Educational Fund PEPTIDE COMPOSITIONS AND METHODS OF USE THEREOF
US12545728B2 (en) * 2019-02-04 2026-02-10 Lonza Sales Ag Treatment of cancer metastasis by targeting exosome proteins

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008535853A (ja) * 2005-04-07 2008-09-04 ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド 癌関連遺伝子
US20120100162A1 (en) * 2006-09-15 2012-04-26 Accentia Biopharmaceuticals, Inc. Cyclophosphamide in Combination with Immune Therapeutics
WO2012021840A2 (en) * 2010-08-13 2012-02-16 Biovest International, Inc. Materials and methods for designing autologous idiotype vaccines and treatment of b-cell malignancies

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CANCER RESEARCH, vol. 63(10), JPN6024046642, 2003, pages 2665 - 2674, ISSN: 0005660060 *
CELL RESEARCH, vol. 25, JPN6025032481, 2015, pages 370 - 385, ISSN: 0005804095 *
MOL. CANCER RES., vol. 12(12), JPN6024046643, 2014, pages 1840 - 1850, ISSN: 0005660059 *
MOL. CELL BIOL., vol. 27(21), JPN6024046645, 2007, pages 7718 - 7726, ISSN: 0005804094 *

Also Published As

Publication number Publication date
EP4081253A4 (en) 2023-09-06
AU2020413633A1 (en) 2022-08-18
TW202135861A (zh) 2021-10-01
MX2022008061A (es) 2022-10-27
CN115551549A (zh) 2022-12-30
KR20220151161A (ko) 2022-11-14
US20230056288A1 (en) 2023-02-23
CA3165908A1 (en) 2021-07-01
WO2021129744A1 (en) 2021-07-01
IL294280A (en) 2022-08-01
EP4081253A1 (en) 2022-11-02

Similar Documents

Publication Publication Date Title
EP3283527B1 (en) Combination therapy for cancer
JP2025108413A (ja) Psgl-1アンタゴニスト及びその使用
JP7719799B2 (ja) 抗ガレクチン-9抗体およびその使用
US12617860B2 (en) Anti-TNFR2 antibody and uses thereof
AU2022308421A1 (en) Anti-tnfr2 antibody and uses thereof
JP2023537131A (ja) Igsf8を標的化することによる自己免疫疾患および癌を治療するための組成物および方法
JP2025527535A (ja) 抗ccr8抗体およびその使用
WO2021129744A1 (en) Compositions and methods for treating autoimmune diseases and cancers by targeting igsf8
RU2840501C1 (ru) Анти-галектин-9 антитело и его применение
HK40092079A (en) Anti-tnfr2 antibody and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220729

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220708

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231213

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231213

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241120

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250217

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250515

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250807

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251106

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20251110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20251110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251224

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260623

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20260623